Articles

Bortezomib-based immunosuppression after reduced-intensity conditioning hematopoietic stem cell transplantation: randomized phase II results

Division of Hematologic Malignancies, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA
Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute and Harvard School of Public Health, Boston, MA
Division of Hematologic Malignancies, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA
Division of Hematologic Malignancies, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA
Division of Hematologic Malignancies, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA
Division of Hematologic Malignancies, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA
Division of Hematologic Malignancies, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA
Division of Hematologic Malignancies, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA
Division of Hematologic Malignancies, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA
Division of Hematologic Malignancies, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA
Division of Hematologic Malignancies, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA
Division of Hematologic Malignancies, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA
Massachusetts General Hospital Cancer Center, Boston, MA
Massachusetts General Hospital Cancer Center, Boston, MA
Beth Israel Deaconess Hospital Cancer Center, Boston, MA
Division of Hematologic Malignancies, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA
University of Minnesota Masonic Cancer Center and Department of Pediatrics, Division of Blood and Marrow Transplantation, Minneapolis, MN, USA
Division of Hematologic Malignancies, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA
Division of Hematologic Malignancies, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA
Division of Hematologic Malignancies, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA
Vol. 103 No. 3 (2018): March, 2018 https://doi.org/10.3324/haematol.2017.176859